Cytotoxicity News and Research

RSS

Study finds FDA-approved drug has potent antiviral activity against SARS-CoV-2 and variants of concern

A new study aimed to examine the antiviral potential of atovaquone against the original SARS-CoV-2 strain and other variants of concern.

25 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

New high-throughput assay could help development of anti-COVID-19 drugs

In a recent study, researchers develop a new high-throughput assay that allows for rapid screening of potential inhibitors.

13 Oct 2021

A mucoadhesive polymer with anti-SARS-COV-2 activity in vitro and in vivo

The team has evaluated a low molecular weight chitosan derivative as a candidate preventing the viral entry into mammalian nasal epithelial cells to limit the spread of COVID-19.

12 Oct 2021

Antiviral activity of wheat germ Agglutinin against SARS-CoV-2

A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.

4 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

The findings from this study suggest that HPNs may inhibit viral replication and budding.

27 Sep 2021

Study shows how SARS-CoV-2 viral proteases can be targeted to stop virus replication

Researchers at the University of Liverpool have shown how SARS-CoV-2 viral proteases attack the host cell, and how this can be targeted to stop virus replication in cell culture using existing drugs.

21 Sep 2021

Careful pipetting reduces the stress on cells in culture

Cell viability, defined as the proportion of live cells in a sample, is a fundamental consideration in all cell culture techniques.

From INTEGRA Biosciences 21 Sep 2021

The influence of prior seasonal coronavirus infection on disease severity in COVID-19

A new study posted to the bioRxiv* server attempted to explore anti-spike IgG responses, Fc-gamma receptor (FcγR) activation, IgG targeting of immunodominant regions, and recall responses due to seasonal hCoV infections in non-hospitalized COVID-19 patients.

20 Sep 2021

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

A new study describes a small molecule referred to as RG10 that may have potent antiviral activity against SARS-CoV-2 in human cells.

16 Sep 2021

Neutralizing monoclonal antibodies provide Fc receptor-independent SARS-CoV-2 protection in Hamsters

A study published in the journal mBio analyzes the capacity of the neutralizing MAb 2B04 to protect different antibody titers.

16 Sep 2021

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

A new paper describes the results of a randomized controlled trial of CP in adult COVID-19 patients on oxygen when used within 12 days of the onset of respiratory symptoms.

14 Sep 2021

Artemisia plant extract prevents SARS-CoV-2 replication in vitro

A new study describes the beneficial effect of an extract of Artemisia annua when used to treat cells in culture exposed to SARS-CoV-2.

13 Sep 2021

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

This study revealed that the CV3-13 antibody can mediate Fc effector functions against S protein-expressing cells.

13 Sep 2021

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.

3 Sep 2021

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

30 Aug 2021

Compounds from medicinal mushrooms may be our future weapon against SARS-CoV-2

Certain steroid-like compounds from Taiwan's endemic medicinal mushrooms (known as antcins) may inhibit a host cell receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, thus, prevent viral infection and subsequent development of the coronavirus disease (COVID-19), reports a new study published in the MDPI's journal Plants.

24 Aug 2021

Peptoids could one day cure or prevent herpes, COVID-19

In addition to antibodies and white blood cells, the immune system deploys peptides to fight viruses and other pathogens.